While the different effects of bortezomib on spleen weight may be specific to the etiology of the these autoimmune disease models, studies investigating proteasome inhibition specifically in preclinical models of hypertension (47, 49, 50), including angiotensin II infusion (48), have not reported spleen weight. Here, AGT is linked to hypertensive disorder.